Inhibrx Biosciences vs SAB Biotherapeutics
INBX and SABS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INBX and SABS compare
Inhibrx Biosciences is the larger company, worth 4.6 times as much as SAB Biotherapeutics ($1.2B against $269M).
SAB Biotherapeutics scores higher on the StockData Score (8 against 1 for Inhibrx Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INBX | SABS |
|---|---|---|
| Size and price | ||
| Market cap | $1.2B | $269M |
| Share price | $83.30 | $2.96 |
| Change, 1 year | 13.6% | −13.2% |
| Change, 5 years | 92.3% | −97.3% |
| Beta (5Y) | 1.70 | 1.38 |
| Employees | 110 | 86 |
| StockData Score | ||
| Total score | 1 | 8 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 1.3× |
| FCF yield | −10.8% | – |
| Growth | ||
| Revenue growth, 5Y average | −36.8% | – |
| Net income growth (TTM) | – | −530% |
| Profitability | ||
| Return on equity | – | −42.8% |
| Return on invested capital | – | −83.4% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −5.9× | – |
| Current ratio | 7.58 (better) | 7.28 |
| Altman Z-score | −0.76 | 4.78 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 97.4% | 75.2% |
| Held by insiders | 35.4% | 30.2% |
| Insider net buying, 12 months | $6.1M | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 35.7% | 7.9% |
Go deeper
- INBX stock overview
- INBX income statement
- INBX valuation and score
- SABS stock overview
- SABS income statement
- SABS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.